We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-4.45%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.08B
AUM Growth
+$322M
Cap. Flow
+$648M
Cap. Flow %
21%
Top 10 Hldgs %
37.4%
Holding
321
New
89
Increased
78
Reduced
45
Closed
96

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32M
2
CCCC icon
C4 Therapeutics
CCCC
+$14.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.1M
4
AMRS
Amyris Inc.
AMRS
+$11M
5
TECH icon
Bio-Techne
TECH
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$14.1M
2
DXCM icon
DexCom
DXCM
+$14.1M
3
ICUI icon
ICU Medical
ICUI
+$14M
4
LIVN icon
LivaNova
LIVN
+$12.2M
5
OLPX
Olaplex Holdings
OLPX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 24.06%
2 Materials 0.35%
3 Industrials 0.17%
4 Consumer Discretionary 0.07%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
101
CALL
STAAR Surgical
STAA
$1.27B
$6.79M 0.22%
+85,000
New +$6.33M
TELA icon
102
TELA Bio
TELA
$32.3M
$6.6M 0.21%
567,420
+3,300
+0.6% +$39.9K
ATAI icon
103
AtaiBeckley Inc
ATAI
$2.68B
$6.51M 0.21%
1,278,105
+725,324
+131% +$4.03M
EVH icon
104
Evolent Health
EVH
$471M
$6.46M 0.21%
+200,000
New +$5.24M
PRVA icon
105
Privia Health
PRVA
$2.75B
$6.42M 0.21%
240,200
+17,707
+8% +$418K
APYX icon
106
Apyx Medical
APYX
$126M
$6.42M 0.21%
982,683
+140,100
+17% +$1.38M
SOPH icon
107
SOPHiA GENETICS
SOPH
$635M
$6.42M 0.21%
+829,930
New +$9.32M
MIST icon
108
Milestone Pharmaceuticals
MIST
$141M
$6.34M 0.21%
987,411
+55,900
+6% +$349K
SDGR icon
109
CALL
Schrodinger
SDGR
$1.39B
$6.31M 0.2%
+185,000
New +$5.62M
DNA icon
110
PUT
Ginkgo Bioworks
DNA
$486M
$6.04M 0.2%
+37,500
New +$7.3M
GILD icon
111
PUT
Gilead Sciences
GILD
$168B
$5.95M 0.19%
+100,000
New +$6.39M
BEAM icon
112
PUT
Beam Therapeutics
BEAM
$2.76B
$5.73M 0.19%
+100,000
New +$6.56M
RCEL icon
113
Avita Medical
RCEL
$251M
$5.72M 0.19%
+674,316
New +$6.21M
MASS icon
114
908 Devices
MASS
$414M
$5.63M 0.18%
296,288
-16,658
-5% -$286K
STXS icon
115
Stereotaxis
STXS
$139M
$5.52M 0.18%
1,479,292
-152,807
-9% -$721K
COO icon
116
Cooper Companies
COO
$15B
$5.43M 0.18%
+52,000
New +$5.23M
SNCE
117
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$5.38M 0.17%
+50,320
New +$7.88M
ZTS icon
118
PUT
Zoetis
ZTS
$30.4B
$5.28M 0.17%
+28,000
New +$5.54M
NVCR icon
119
PUT
NovoCure
NVCR
$2.05B
$5.2M 0.17%
62,700
-31,100
-33% -$2.29M
APLS
120
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$5.08M 0.16%
+100,000
New +$4.41M
RCM
121
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.04M 0.16%
+188,455
New +$4.62M
HCA icon
122
PUT
HCA Healthcare
HCA
$89.8B
$5.01M 0.16%
20,000
-30,000
-60% -$7.53M
MEDP icon
123
PUT
Medpace
MEDP
$16.7B
$4.91M 0.16%
30,000
-6,800
-18% -$1.12M
CCCC icon
124
CALL
C4 Therapeutics
CCCC
$480M
$4.85M 0.16%
+200,000
New +$4.86M
ACAD icon
125
CALL
Acadia Pharmaceuticals
ACAD
$5.07B
$4.84M 0.16%
+200,000
New +$4.84M
3 4
5
6 7

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Pura Vida Investments held 321 positions worth $3.08B, up 12% from $2.76B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $648M of net new capital in Q1 2022, opening 89 new positions and adding to 78 existing holdings. Its largest new stake was Biogen: 147,135 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 30% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was ICU Medical, an estimated $14M trimmed.

  • Pura Vida Investments's largest Q1 2022 buy was Biogen: 147,135 shares worth $31M.
  • Pura Vida Investments added most to C4 Therapeutics in Q1 2022, an estimated $14.5M increase.
  • Pura Vida Investments's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $14M.
  • Pura Vida Investments fully exited Natera in Q1 2022, selling an estimated $14.1M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $3.08B portfolio in Q1 2022.
  • Pura Vida Investments opened 89 new positions and closed 96 in Q1 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $3.08B.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.